What does the Biocon Limited (BIOCON) stock page cover?

Biocon Limited on Anvest includes delayed price context, valuation ratios, a one-year price range, and section-level research data when available.

What are the current headline metrics for BIOCON?

Biocon Limited is currently shown with a delayed price near ₹351.8, P/E 124.75.

Does the BIOCON page provide investment advice?

No. The BIOCON page is built for research, comparison, and planning. It does not publish buy, sell, or hold recommendations.

Stocks›Healthcare

Watch Alert

Biocon Limited

BIOCON · NSE · Healthcare · As of 30 Oct 2026Delayed / Sandbox EOD Data

₹351.80

−₹0.10 (−0.03%)(1D)

₹318.4052 Week Range₹447.15

Anvest Score

26/100

Valuation

0/100

Quality

8/100

Growth

46/100

Health

55/100

Momentum

37/100

Valuation
0
Quality
8
Growth
46
Health
55
Momentum
37

Loading company profile…

More Page Context

Research at a glance

Biocon Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹351.8

Market cap

₹63,548 Cr

P/E ratio

124.75

P/B ratio

1.68

Dividend yield

Not available

ROE

Not available

RSI 14

46.75

1Y return

Not available

Biocon Limited FAQs

3 topics

Expand

Stocks›Healthcare

Watch Alert

Biocon Limited

BIOCON · NSE · Healthcare · As of 30 Oct 2026Delayed / Sandbox EOD Data

₹351.80

−₹0.10 (−0.03%)(1D)

₹318.4052 Week Range₹447.15

Anvest Score

26/100

Valuation

0/100

Quality

8/100

Growth

46/100

Health

55/100

Momentum

37/100

Valuation
0
Quality
8
Growth
46
Health
55
Momentum
37

AI Company ProfileSign in to generate AI briefing

AI Snapshot

Biocon Limited develops and commercializes biological therapeutics. The company leverages innovative technology and global manufacturing to reduce costs and improve healthcare outcomes, focusing on biosimilars across various chronic therapeutic segments.

BiotechnologyGlobal FootprintFounded:1978CEO/MD:Siddharth MittalHQ:Bengaluru, Karnataka

Business profile as of 2026-08-25

Business at a Glance

The company has commercialized 10 biosimilars globally and maintains a robust development pipeline of over 20 biosimilar assets.
These span diabetes, oncology, immunology, and ophthalmology, with a focus on advancing patient health and sustainability.

Revenue growth: +10.9%FY26 growth+14.8%3Y CAGR
EPS growth: -66.7%FY26 growth-10.0%3Y CAGR
CFO / PAT: 5.41×FY26

What Looks Strong

GrowthRevenue grew at +14.8% CAGR over three years.
Cash FlowOperating cash flow was 5.41× total net profit in FY26.
MarketShareholder returns have comfortably outpaced the Nifty 500 benchmark over the 3-year period.

What to Watch

EarningsNet profit fell about 74% in FY26 (consolidated: ₹1,429 cr → ₹369 cr). Watch margins and one-off items in the next filing.
ValuationThe shares trade at 125× trailing earnings; the multiple assumes sustained high growth and is sensitive to any slowdown.
TrendPrice is 10% below its 200-day moving average, indicating a weak long-term price trend.

Segment revenue, FY26 (consolidated, as filed): Biosimilars 60%; CRDMO 22%; Generics 18%.
Share of segment profit before interest and tax, FY26: Biosimilars 55%; CRDMO 45%. Generics made a segment loss of ₹135 cr.
Biocon generates revenue by developing and manufacturing complex biopharmaceutical products, including biosimilars and novel biologics, which are then sold globally.

FY26 (consolidated): revenue ₹16,927 cr, up 11% from ₹15,262 cr in FY25; net profit ₹369 cr, down 74% from ₹1,429 cr in FY25.
FY26 (consolidated): operating cash flow ₹1,994 cr (5.4× net profit); debt/equity 0.40×.

Biocon Limited emphasizes advancing patient health, societal well-being, and environmental sustainability, aligning with global ESG and UN Sustainable Development Goals

Loading company profile…

More Page Context

Research at a glance

Biocon Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹351.8

Market cap

₹63,548 Cr

P/E ratio

124.75

P/B ratio

1.68

Dividend yield

Not available

ROE

Not available

RSI 14

46.75

1Y return

Not available

Biocon Limited FAQs

3 topics

Expand

AI Company ProfileSign in to generate AI briefing

AI Snapshot

BiotechnologyGlobal FootprintFounded:1978CEO/MD:Siddharth MittalHQ:Bengaluru, Karnataka

Business profile as of 2026-08-25

Business at a Glance

The company has commercialized 10 biosimilars globally and maintains a robust development pipeline of over 20 biosimilar assets.
These span diabetes, oncology, immunology, and ophthalmology, with a focus on advancing patient health and sustainability.

Revenue growth: +10.9%FY26 growth+14.8%3Y CAGR
EPS growth: -66.7%FY26 growth-10.0%3Y CAGR
CFO / PAT: 5.41×FY26

What Looks Strong

GrowthRevenue grew at +14.8% CAGR over three years.
Cash FlowOperating cash flow was 5.41× total net profit in FY26.
MarketShareholder returns have comfortably outpaced the Nifty 500 benchmark over the 3-year period.

What to Watch

EarningsNet profit fell about 74% in FY26 (consolidated: ₹1,429 cr → ₹369 cr). Watch margins and one-off items in the next filing.
ValuationThe shares trade at 125× trailing earnings; the multiple assumes sustained high growth and is sensitive to any slowdown.
TrendPrice is 10% below its 200-day moving average, indicating a weak long-term price trend.

Segment revenue, FY26 (consolidated, as filed): Biosimilars 60%; CRDMO 22%; Generics 18%.
Share of segment profit before interest and tax, FY26: Biosimilars 55%; CRDMO 45%. Generics made a segment loss of ₹135 cr.
Biocon generates revenue by developing and manufacturing complex biopharmaceutical products, including biosimilars and novel biologics, which are then sold globally.

FY26 (consolidated): revenue ₹16,927 cr, up 11% from ₹15,262 cr in FY25; net profit ₹369 cr, down 74% from ₹1,429 cr in FY25.
FY26 (consolidated): operating cash flow ₹1,994 cr (5.4× net profit); debt/equity 0.40×.

Biocon Limited emphasizes advancing patient health, societal well-being, and environmental sustainability, aligning with global ESG and UN Sustainable Development Goals

Biocon Limited

Research at a glance

Biocon Limited FAQs

Biocon Limited

Business at a Glance

What Looks Strong

What to Watch

Research at a glance

Biocon Limited FAQs

Related paths

Related insights

ANTHEM

ONESOURCE

CONCORDBIO

Monte Carlo Simulation & Walk-Forward Optimization for Indian Stock Strategies

Business at a Glance

What Looks Strong

What to Watch